

Axsome Therapeutics, Inc. Securities Litigation
c/o Strategic Claims Services
600 N. Jackson St., Suite 205
Media, PA 19063

**Court-Ordered Legal Notice
Forwarding Service Requested**

*A federal court authorized this
notice. This is not a solicitation
from a lawyer.*

*This Notice may affect your legal
rights. You may be entitled to a
payment from this securities
class action settlement.*

In re Axsome Therapeutics, Inc. Securities Litigation, Case No.: 1:22-cv-03925-LGS
THIS CARD PROVIDES ONLY LIMITED INFORMATION ABOUT THE SETTLEMENT.
PLEASE VISIT WWW.STRATEGICCLAIMS.NET/AXSOME/ OR CALL 1-866-274-4004 FOR MORE INFORMATION.

The U.S. District Court for the Southern District of New York (“Court”) has preliminarily approved a Settlement of claims against Axsome Therapeutics, Inc. (“Axsome”), and certain of its officers (collectively, “Defendants”). The proposed Settlement would resolve a class action lawsuit alleging that, in violation of the federal securities laws, Defendants made material misrepresentations and/or omissions to the public about Axsome’s drug candidate AXS-07 and its New Drug Application to the U.S. Food and Drug Administration for AXS-07, causing damage to settlement class members. Defendants deny any wrongdoing.

You received this notice because you or someone in your family or household may have purchased or acquired Axsome common stock between May 10, 2021, and April 22, 2022, inclusive (“Class Period”). The Settlement provides that, in exchange for dismissal and release of claims known or unknown against Defendants, Defendants will pay or cause to be paid into a settlement fund \$7,750,000.00 (“Settlement Fund”). The Settlement Fund, less attorneys’ fees and expenses, and a compensatory award to Lead Plaintiffs, will be divided among settlement class members who timely submit valid Proof of Claim and Release Forms (“Claim Form”). For a full description of the Settlement and your rights and to make a claim, please view the Stipulation of Settlement and obtain a copy of the Notice of Pendency and Proposed Settlement of Class Action (“Long Notice”) and Claim Form by visiting the website: www.strategicclaims.net/Axsome/. You may also request copies of the Long Notice and Claim Form from the Claims Administrator by: (1) mail: *Axsome Therapeutics, Inc. Securities Litigation*, c/o Strategic Claims Services, P.O. Box 230, 600 N. Jackson St, Ste. 205, Media, PA 19063; (2) toll-free phone: (866) 274-4004; (3) fax: (610) 565-7985; or (4) email: info@strategicclaims.net.

To qualify for payment, you must submit a Claim Form to the Claims Administrator. CLAIM FORMS ARE DUE BY FEBRUARY 3, 2026 TO: *AXSOME THERAPEUTICS, INC. SECURITIES LITIGATION*, C/O STRATEGIC CLAIMS SERVICES, P.O. BOX 230, 600 N. JACKSON ST, STE 205, MEDIA, PA 19063, OR SUBMITTED ONLINE AT WWW.STRATEGICCLAIMS.NET/AXSOME/. If you DO NOT want to be legally bound by the Settlement, you must exclude yourself from the Settlement Class by January 13, 2026 or you will not be able to sue the Defendants about the legal claims in this case. If you exclude yourself, you cannot get money from this Settlement. If you stay in the Settlement, you may object to it by January 13, 2026. The Long Notice explains how to exclude yourself or to object.

The Court will hold a hearing (the “Settlement Hearing”) in this case on February 10, 2026 at 2:30 p.m. at 40 Foley Square, Courtroom 1106, New York, NY 10007, to consider whether to approve the Settlement, the Plan of Allocation, a request by Lead Counsel for attorneys’ fees up to 30%, plus actual expenses up to \$250,000, and awards to Lead Plaintiffs not to exceed \$30,000. You may, but do not have to, attend the hearing and ask to be heard by the Court. The Court reserves the right to hold the Settlement Hearing telephonically or by other virtual means. For more information, call 1-866-274-4004, or visit the website, www.strategicclaims.net/Axsome/.